Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: A case report
AN Bourkas, C Sibbald - SAGE Open Medical Case Reports, 2022 - journals.sagepub.com
AN Bourkas, C Sibbald
SAGE Open Medical Case Reports, 2022•journals.sagepub.comThis case report describes the first successful treatment of alopecia areata and atopic
dermatitis with the Janus kinase 1 inhibitor upadacitinib in a paediatric patient. After minimal
response to topical corticosteroids and spironolactone, improvements in hair growth on the
scalp and body were noted after only 6 weeks of upadacitinib treatment.
dermatitis with the Janus kinase 1 inhibitor upadacitinib in a paediatric patient. After minimal
response to topical corticosteroids and spironolactone, improvements in hair growth on the
scalp and body were noted after only 6 weeks of upadacitinib treatment.
This case report describes the first successful treatment of alopecia areata and atopic dermatitis with the Janus kinase 1 inhibitor upadacitinib in a paediatric patient. After minimal response to topical corticosteroids and spironolactone, improvements in hair growth on the scalp and body were noted after only 6 weeks of upadacitinib treatment.
Sage Journals以上显示的是最相近的搜索结果。 查看全部搜索结果